• Publications
  • Influence
Estrogen and the risk of breast cancer.
The connection between breast cancer and estrogen has been recognized for more than 100 years, since George Beatson demonstrated that bilateral oophorectomy resulted in the remission of breast cancerExpand
  • 1,025
  • 31
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.
Metabolic reprogramming is a hallmark of cellular transformation, yet little is known about metabolic changes that accompany tumor metastasis. Here we show that primary breast cancer cells displayExpand
  • 235
  • 15
  • PDF
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind,
BACKGROUND Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed the efficacy ofExpand
  • 271
  • 14
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
Background: Decisions about systemic treatment of women with metastatic breast cancer are often based on estrogen receptor (ER), progesterone receptor (PgR), and Her2 status of the primary tumor.Expand
  • 269
  • 9
  • PDF
Palliative treatment of painful bone metastases with MR imaging--guided focused ultrasound.
PURPOSE To evaluate the safety and initial efficacy of magnetic resonance (MR) imaging-guided focused ultrasound for the palliation of pain caused by bone metastases in patients in whom standardExpand
  • 198
  • 9
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer
BackgroundWomen who receive adjuvant chemotherapy for breast cancer develop fatigue, and a subset reports cognitive impairment. Methylphenidate is reported to improve fatigue and to decreaseExpand
  • 141
  • 7
The use of complementary and alternative medicines among patients with locally advanced breast cancer – a descriptive study
BackgroundComplementary and alternative medicine (CAM) use is common among cancer patients. This paper reviews the use of CAM in a series of patients with locally advanced breast cancerExpand
  • 120
  • 7
  • PDF
Tamoxifen ("Nolvadex"): a review.
Tamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include theExpand
  • 189
  • 5
Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
BACKGROUND Changes in the receptor profile between primary and metastatic breast cancer tissue have been suggested. The degree of hormone receptor discordance in archival paired pathological samplesExpand
  • 144
  • 4
Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast
Background: PI3K pathway activation is a hallmark of hormone receptor-positive (HR+) BC cells resistant to endocrine therapy (ET). Preclinical and early clinical data suggest that combining theExpand
  • 84
  • 4